OR WAIT 15 SECS
Staidson and Pivotal have announced a new strategic collaboration to assess Staidson´s investigational product BDB-001 in a Europe-based clinical trial in progressive severe COVID-19 patients caused by SARS-CoV-2. This clinical trial is a multicenter, open-label, randomized and controlled study. Sixty patients will be enrolled in the trial, half of them will be administered the drug and the other half will follow the standard of care used at the corresponding center.
For more information, click here.